Skip to content

Bispectral Index Guiding Etomidate Used in Children Aged 3 to 10 for Clinical Anesthesia Induction

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02182648
Enrollment
120
Registered
2014-07-08
Start date
2014-10-31
Completion date
Unknown
Last updated
2014-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bispectral Index, Etomidate, Induction, Pediatric

Brief summary

This research through using bispectral index to guide the induced dose and speed of etomidate lipid emulsion for pediatric total venous anesthesia,and to provide a reference for clinical anesthesia physician.

Interventions

DRUGetomidate

1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia. 2. infusion of etomidate at 2 minutes before anesthesia induction

DRUGpropofol

1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia. 2. infusion of propofol at 2 minutes before anesthesia induction

DRUGsevoflurane

1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia. 2. inhale sevoflurane for anesthesia induction and maintenance

Sponsors

Henan Provincial People's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
3 Years to 10 Years
Healthy volunteers
No

Inclusion criteria

1. obtain informed consent; 2. undergoing elective hypospadias repair surgery under general anesthesia; 3. American society of anesthesiologists (ASA) class I-II; 4. aged between 3-10 years old; 5. BMI is 18.5-30 kg/m2;

Exclusion criteria

1. systolic blood pressure≥180 mmHg or\<90 mmHg, diastolic blood pressure≥110 mmHg or\<60 mmHg; 2. serious heart, brain, liver, kidney, lung, endocrine diseases or serious infections; 3. long-term use of hormone or a history of adrenal cortex inhibition; 4. suspected or confirmed difficult airway; 5. suspected or confirmed abuse of narcotic analgesic drugs, psychotropic drugs; 6. neuromuscular disease; 7. mental instability, or have a mental illness; 8. allergic to investigational products or with other contraindication 9. participated in other study within 30 days

Design outcomes

Primary

MeasureTime frameDescription
the drugs used timefrom the beginning of induction to Bispectral Index < 50,expected to be within 1 minutethe injection time of etomidate and propofol, and the inhale time of sevoflurane during anesthesia induction
degree of inflammation reactionbaseline,5 minutes after indution,5 minutes before operation end,30 mimutes、24h and 48h after operationserum levels of interleukin 6 and tumor necrosis factor α will be measured at each time point using ELISA method
adrenal functionbaseline,5 minutes after indution,5 minutes before operation end,30 mimutes、24h and 48h after operationserum level of cortisol will be measured at each time point using radioimmunoassay
the amount of drugsfrom the beginning of induction to Bispectral Index < 50,up to 5 minutesthe amount of etomidate,propofol and sevoflurane used in anesthesia induction
numbers of muscular fibrillationfrom the beginning of induction to Bispectral Index < 50,up to 5 minutesnumbers of muscular fibrillation in anesthesia induction

Secondary

MeasureTime frameDescription
sedation degreefrom the beginning of induction to skin closure, up to 3 hoursBispectral index,train-of-four stimulation and the temperature recorded at 4 time points including before anesthesia induction,before endotracheal intubation,after endotracheal intubation and after operation immediately
hemodynamic parametersfrom the beginning of induction to skin closure, up to 3 hoursheart rate,blood pressure,electrocardiogram and pulse oxygen saturation recorded at 4 time points including before anesthesia induction,before endotracheal intubation,after endotracheal intubation and after operation immediately

Contacts

Primary ContactEnqiang Chang
clinicaltriallh@163.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026